Overcoming roadblocks in the development of vaccines for leishmaniasis

Paul M. Kaye*, Sakshi Mohan, Carsten Mantel, Melissa Malhame, Paul Revill, Epke Le Rutte, Vivak Parkash, Alison M. Layton, Charles J.N. Lacey, Stefano Malvolti

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

2 Citations (Scopus)
1 Downloads (Pure)

Abstract

Introduction: The leishmaniases represent a group of parasitic diseases caused by infection with one of several species of Leishmania parasites. Disease presentation varies because of differences in parasite and host genetics and may be influenced by additional factors such as host nutritional status or co-infection. Studies in experimental models of Leishmania infection, vaccination of companion animals and human epidemiological data suggest that many forms of leishmaniasis could be prevented by vaccination, but no vaccines are currently available for human use.

Areas covered: We describe some of the existing roadblocks to the development and implementation of an effective leishmaniasis vaccine, based on a review of recent literature found on PubMed, BioRxiv and MedRxiv. In addition to discussing scientific unknowns that hinder vaccine candidate identification and selection, we explore gaps in knowledge regarding the commercial and public health value propositions underpinning vaccine development and provide a route map for future research and advocacy.

Expert opinion: Despite significant progress, leishmaniasis vaccine development remains hindered by significant gaps in understanding that span the vaccine development pipeline. Increased coordination and adoption of a more holistic view to vaccine development will be required to ensure more rapid progress in the years ahead.

Original languageEnglish
Pages (from-to)1419-1430
Number of pages12
JournalExpert Review of Vaccines
Volume20
Issue number11
Early online date2 Nov 2021
DOIs
Publication statusPublished - 2021

Bibliographical note

Funding Information:
PM Kaye is supported by a Wellcome Trust Senior Investigator Award (WT1063203). PM Kaye, AM Layton and CJN Lacey and V Parkash and are in receipt of support from the Wellcome Trust (WT108518) and the EDCTP2 programme funded by the European Union (grant number RIA2016V-1640; PREV_PKDL) to support the development of leishmaniasis vaccines and from the UK Medical Research Council/Department for International Development to develop a controlled human infection model for sand fly-transmitted cutaneous leishmaniasis (MR/R014973/1). EA Le Rutte is supported by the Bill and Melinda Gates Foundation -funded NTD Modelling Consortium (OPP1184344). S Mohan and P Revill were supported by a Medical Research Council Global Challenges Research Fund award (MR/P028004/1). The authors acknowledge the contributions made by all researchers involved in the development of vaccines for leishmaniasis and apologize that due to considerations of space, not all works could be cited here.

Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Fingerprint

Dive into the research topics of 'Overcoming roadblocks in the development of vaccines for leishmaniasis'. Together they form a unique fingerprint.

Cite this